Goods & Services

Arranging and conducting of educational seminars in the field of collaborations across business, academic, government, and nonprofit sectors to meet global demand for more energy and lower carbon emissions

Goods & Services

Providing courses of instruction at the undergraduate level; Providing courses of instruction at the post-graduate level; Providing courses of instruction at the graduate level; Providing courses of instruction at the post-graduate level for professional schools; Providing courses of instruction at the graduate level for continuing education

Goods & Services

Arranging and conducting of seminars in the field of collaborations across business, academic, government, and nonprofit sectors to meet global demand for more energy and lower carbon emissions

Abstract

Disclosed herein are various embodiments relating to the treatment of idiopathic pulmonary fibrosis in a subject in need thereof through the administration of composition comprising an anti-CTLA-4 antibody. In certain embodiments, the anti-CTLA-4 antibody is ipilimumab.

IPC Classes  ?

• A61P 11/00 - Drugs for disorders of the respiratory system
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue

Abstract

A metalens includes a substrate having a first pixel and a second pixel thereon. The first pixel includes a first periodic array of first antennae each having a first width, a first height, a first electric-dipole resonance, and a first magnetic-dipole resonance. The second pixel includes a second periodic array of second antennae each having a second width and a second height, a second electric-dipole resonance, and a second magnetic-dipole resonance. The first and second periodic arrays have a first period and a second period, respectively. At least one of (i) the first and second widths, (ii) the first and second heights are unequal, and (iii) the first and second periods, are unequal. For each resonance, the center wavelengths of the resonance differs from a design wavelength of the metalens, at which the metalens operates, by less than four times a linewidth of the resonance.

IPC Classes  ?

• G02B 3/00 - Simple or compound lenses
• G02B 1/00 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements

Abstract

Methods and devices for controlling polymerization reactions using the controlled addition of oxygen to a reactor. The method may include providing a reactor comprising one or more chemical components suitable for facilitating a polymerization reaction and continuously measuring one or more polymer characteristics of polymers generated by the polymerization reaction in the reactor. The method may also include determining, using a control algorithm, based on the continuous measurements of one or more polymer characteristics, the amount of oxygen to add to the reactor at one or more time points during the polymerization reaction in order to cause the one or more polymer characteristics to follow a predetermined target trajectory.

IPC Classes  ?

• B01J 19/00 - Chemical, physical or physico-chemical processes in generalTheir relevant apparatus

Abstract

A method of preparing a therapeutic mesenchymal stem cell composition is described where the MSCs are selected and isolated with a gene signature. The gene signature can be used to provide MSCs that have improved therapeutic properties by removing aging MSCs at early passages.

IPC Classes  ?

• C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells

Abstract

An assay for detection of a target extracellular vesicle in a sample advantageously utilizes copper shells grown on gold nanostructures labeling the target extracellular vesicle to enhance the scattering signal and thereby improve assay sensitivity.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/553 - Metal or metal coated
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

Described herein are aqueous-based foams for use in controlling algal blooms.

IPC Classes  ?

• A01N 25/16 - Foams
• A01N 25/30 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
• A01P 13/00 - HerbicidesAlgicides
• A01N 25/04 - Dispersions or gels

Abstract

Described herein devices and systems for performing non-contact mixing of solutions during spectroscopic measurement, as well as methods of using thereof.

IPC Classes  ?

• B01F 27/80 - Mixers with rotary stirring devices in fixed receptaclesKneaders with stirrers rotating about a substantially vertical axis
• B01F 33/501 - Movable mixing devices, i.e. readily shifted or displaced from one place to another, e.g. portable during use
• C12M 1/02 - Apparatus for enzymology or microbiology with agitation meansApparatus for enzymology or microbiology with heat exchange means
• B01F 27/11 - Stirrers characterised by the configuration of the stirrers

Abstract

The present disclosure relates generally to a supercapacitor comprising an electrode having an intercalated MXene material, and a room temperature ionic liquid (RTIL), the supercapacitor having superior electrochemical performance.

IPC Classes  ?

• H01G 11/62 - Liquid electrolytes characterised by the solute, e.g. salts, anions or cations therein
• H01G 11/26 - Electrodes characterised by their structure, e.g. multi-layered, porosity or surface features
• H01G 11/86 - Processes for the manufacture of hybrid or EDL capacitors, or components thereof specially adapted for electrodes

Abstract

Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)). Other embodiments include compositions (e.g. pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating. Further embodiments include methods for making the inventive compound. Additional embodiments of the invention are also discussed herein.

IPC Classes  ?

• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure provides methods for predicting drug resistance in a subject with a Pseudomonas infection based on the detection of antibiotic-induced mutational signatures of Pseudomonas species.

IPC Classes  ?

• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61K 31/424 - Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
• A61K 31/47 - QuinolinesIsoquinolines
• A61P 11/00 - Drugs for disorders of the respiratory system
• C12Q 1/6869 - Methods for sequencing

Abstract

An optoelectronic device includes a thin film of a transition-metal dichalcogenide, a first electrode made of a first metal directly contacting the thin film, and a second electrode made of a second metal directly contacting the thin film. The first metal is molybdenum, titanium, aluminum, tantalum, scandium, or yttrium. The second metal is platinum, nickel, palladium, gold, or cobalt. Depending on the type and doping of the transition-metal dichalcogenide, one of the first and second metals forms an electron selective layer with the transition-metal dichalcogenide and the other of the first and second metals forms a hole selective layer with the transition-metal dichalcogenide. The thin film may be a monolayer or multilayer. The transition-metal dichalcogenide may be molybdenum disulfide. The thin film may be grown via chemical vapor deposition and have an area of 0.25 cm2 or more.

IPC Classes  ?

• H10F 77/20 - Electrodes
• H10F 10/18 - Photovoltaic cells having only Schottky potential barriers

Abstract

Glycosylated, cyclic peptides of Formula (I): A1-cyclo[A2-A3-A4-A5]-A6-O-Carb, Formula (II): A1-cyclo[A5-A3-A4-A2]-A6-O-Carb, and pharmaceutically acceptable salts thereof, are described herein, which are useful, e.g., in treating pain. In some embodiments A1 is L-Tyr; A2 is a D-Lys, D-Orn, D-Dab, or D-Dpr; A3 is L-Trp; A4 is L-Phe, A5 is an amino acid residue selected from the group consisting of Asp, Glu, iso-Asp, and iso-Glu; A6 is (a) a hydroxy-substituted amino acid residue (HO-AA), or (b) an oligopeptide comprising 2 to 5 amino acid residues comprising the HO-AA; Carb is a carbohydrate group bonded to the sidechain oxygen of the HO-AA by a β3-D-glycosidic bond, and the C-terminus of A6 optionally is amidated, e.g., as a primary amide.

IPC Classes  ?

• C07K 7/64 - Cyclic peptides containing only normal peptide links
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 25/04 - Centrally acting analgesics, e.g. opioids

Abstract

Disclosed herein are methods for determining whether a patient is suffering from or is at risk for Pneumocystis jirovecii pneumonia (PIP) infection. The methods of the present technology are based on detecting expression levels of the P. jirovecii mitochondrial genes Orf 195, Coxl, Atp6, Cox3, Atp9, Nad5, Nad4, Nad2, Cox2, axxA Nadl in biological samples such as blood samples or oral swabs. Kits for use in practicing the methods are also provided.

IPC Classes  ?

• C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 9/22 - Ribonucleases
• C12Q 1/6818 - Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer

Abstract

The present disclosure relates to compositions including or obtained from genetically modified bacterial host cells (e.g., E. coli) and methods for using the same for cell-free bacteriophage synthesis (CFBS). In particular, the present technology relates to genetically modified E. coli that overexpress one or more of translation initiation factor IF-3 (infC), OxyS and CyaR and/or repress RecC subunit exonuclease RecBCD, and methods for using the same to obtain improved CFBS yields.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 1/06 - Lysis of microorganisms
• C12N 1/20 - BacteriaCulture media therefor
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• C12R 1/19 - Escherichia coli

Abstract

In order to remove the need for manual re-positioning of a sample (e.g., a tissue sample) on a microscope stage, systems and methods for sample positioning are described. A sample can be attached to a tissue positioning device. Then a microscope can be used to take a plurality of microscopy images (e.g., 2-dimensional, 3-dimensional, etc.) of a surface of the sample in a rotational geometry using the tissue positioning device to facilitate the microscopy.

IPC Classes  ?

• G02B 21/26 - StagesAdjusting means therefor
• G01N 21/64 - FluorescencePhosphorescence
• G02B 21/16 - Microscopes adapted for ultraviolet illumination

Abstract

Systems and methods to construct Quantum Error Correcting codes from Higher Grassmann Codes. The present disclosure is directed to algebraic codes obtained from families of imbeddings of the Grassmannian, constructed as the composition of a diagonal imbedding followed by a Segre imbedding into various high dimensional projective spaces. As a result, a large family of new error correcting codes is obtained, and the parameters of such codes are determined.

IPC Classes  ?

• G06N 10/70 - Quantum error correction, detection or prevention, e.g. surface codes or magic state distillation

Abstract

The present technology relates generally to nucleic acid constructs, including promoter constructs, and methods of preparation thereof, that significantly improve prokaryotic gene expression and regulation thereof.

IPC Classes  ?

• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

Abstract

The present disclosure provides novel antigenic peptides and peptide mixtures, and methods of use for the detection of T. cruzi antibodies in tissue samples and the diagnosis of Chagas disease in a subject.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C07K 14/44 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from protozoa
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Disclosed herein are devices, systems, and methods that relate to conductance and/or conductivity measurement and/or the application of electric fields within the framework of spectroscopic or related measurements on a system consisting of a fluid containing chemical substances, with a focus, not limiting, on biological and synthetic macromolecules and colloids, and biologic drugs.

IPC Classes  ?

• B01F 35/21 - Measuring
• G01N 27/06 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a liquid
• G01N 27/08 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a liquid which is flowing continuously
• A61M 1/14 - Dialysis systemsArtificial kidneysBlood oxygenators

Abstract

The present disclosure relates to configuring computing nodes in a distributed ledger environment (e.g., a blockchain environment). Smart contracts and blockchains are used in a wide variety of application fields. Conventionally, smart contracts are executed on a general-purpose computer, which often underperform for a variety of tasks associated with implementing a blockchain network. The present disclosure describes a novel smart contract system implementable on nodes of a blockchain network in order to provide improved or optimized performance. For example, the smart contract system can leverage instruction-level parallelism as well as transaction-level parallelism during smart contract processing in order to boost its execution performance. Further, the smart contract system can be configured and adapted to different workloads in order to remove bottlenecks. The processes described herein can additionally be implemented on unique hardware uniquely suited for the parallelism involved in processing blockchain transactions.

IPC Classes  ?

• H04L 9/32 - Arrangements for secret or secure communicationsNetwork security protocols including means for verifying the identity or authority of a user of the system
• H04L 9/00 - Arrangements for secret or secure communicationsNetwork security protocols
• G06F 16/182 - Distributed file systems

Abstract

Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)). Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating. Further embodiments include methods for making the inventive compound. Additional embodiments of the invention are also discussed herein.

IPC Classes  ?

• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 35/00 - Antineoplastic agents

Goods & Services

Hats; Sweatshirts; Long-sleeved shirts; Polo shirts; Short-sleeved shirts; T-shirts; Fleece tops; Knit jackets

Abstract

The present disclosure provides modified bacterial cell lysate compositions and methods for using the same for cell-free bacteriophage synthesis (CFBS) to generate a broad range of bacteriophage species. Also disclosed herein are phage engineering methods for converting a lysogenic bacteriophage into a lytic bacteriophage, as well as methods for generating a genetically modified bacteriophage species that targets a broader range of bacterial host strains compared to the wild-type bacteriophage species.

IPC Classes  ?

• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 1/20 - BacteriaCulture media therefor
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• C12N 9/22 - Ribonucleases
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61P 31/04 - Antibacterial agents

Abstract

This application relates to methods of diagnosing Lyme disease. In some embodiments, the methods include detecting levels of at least one antigen in a sample. In some embodiments, the methods include a combination of detecting levels of at least one antigen in a sample and classifying samples using one or more decision trees.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C07K 14/20 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira

Abstract

Provided are recombinant adeno-associated virus (rAAV) vectors comprising a transgene to express Pax4; virions comprising said vectors (rAAV virions); methods of their production; methods of their use, including methods for treating diabetes, increasing insulin production and transdifferentiating α-cells to β-cells; pharmaceutical compositions and kits including same.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• C12N 15/86 - Viral vectors

Abstract

This application relates to methods of diagnosing Lyme disease. In some embodiments, the methods include detecting levels of at least one antigen in a sample. In some embodiments, the methods include a combination of detecting levels of at least one antigen in a sample and classifying samples using one or more decision trees.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present disclosure relates to cancer tumor stroma models with dense stroma and heterogeneous patterns of ECM anisotropy. The invention herein will enable more accurate modeling of tumor pathophysiology, drug delivery, and novel treatment methods impacted by ECM density.

IPC Classes  ?

• C12N 5/09 - Tumour cells
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

2388, and a length-to-thickness ratio greater than one thousand. A semiconductor device includes the TNS nanowire, which has a first position and a second position along its length. The semiconductor device also includes a first metal contact on the TNS nanowire at the first position and a second metal contact on the TNS nanowire at the second position.

IPC Classes  ?

• C30B 11/08 - Single-crystal-growth by normal freezing or freezing under temperature gradient, e.g. Bridgman- Stockbarger method adding crystallising materials or reactants forming it in situ to the melt every component of the crystal composition being added during the crystallisation
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• B82Y 40/00 - Manufacture or treatment of nanostructures
• B22F 1/054 - Nanosized particles
• C30B 29/46 - Sulfur-, selenium- or tellurium-containing compounds
• C30B 29/52 - Alloys

Abstract

Disclosed are designs that enable rapid production of fully vascularized milliscale explant tissues that will enable preservation and expansion of this precious clinical resource and simultaneous investigation of potential biological underpinnings of diseases. Models include triple negative breast cancer or aggressive lung cancer and quiescent lung interstitium integrated in a robust, easily adaptable millifluidic device. Devices will allow any laboratory that use cultures and/or organoids to construct complex multi-tissue/organ systems. Implementation of these devices can model multiple organ pathologies induced by tumor-derived factors.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/09 - Tumour cells

Goods & Services

Sweatshirts; Tank tops; Tee shirts Beverageware; Insulating sleeve holders for beverage cans Organizing and conducting college sport competitions and athletic events

Goods & Services

Sports jerseys Baseballs Organizing and conducting college sport competitions and athletic events

Goods & Services

Educational services, namely, conducting courses of instruction at the undergraduate, graduate, postgraduate and professional levels, seminars, conferences, continuing professional education programs, and workshops in the field of architecture, business, liberal arts, public health, science and engineering, law, medicine and social work; Recreational services in the nature of swimming pools, tennis courts, and fitness, team sport and weight training facilities; Organization of entertainment events in the nature of live musical, dance, theatrical and public speaking events, films, and visual, literary and performing arts presentations; Organizing and conducting college sport competitions and athletic events

Goods & Services

Fleece tops; Sweatshirts; Tee shirts

Goods & Services

Beverageware

Goods & Services

Venture capital financing; Venture capital fund management; Venture capital funding services to emerging and start-up companies

Goods & Services

Hats; Sports jerseys

Abstract

Pneumocystis jiroveciiPneumocystis jirovecii infections in a subject in need thereof.

IPC Classes  ?

• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
• A61P 31/04 - Antibacterial agents
• A61P 31/10 - Antimycotics

Abstract

The disclosure relates to a system and method of using the system to detect and monitor afferent synaptic nerve fiber function in vitro. The disclosure also relates to a method of screening for test agents or compounds that modulate nerve function, such as test agents that modulate pain sensation in a human subject, by exposing one or a plurality of test agents to systems comprising a first and second spheroid, wherein the first spheroid comprise cells from a mammalian dorsal root ganglia and the second spheroid comprises cells from a mammalian spinal cord.

IPC Classes  ?

• C12N 5/0793 - Neurons
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/079 - Neural cells
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Disclosed are devices, systems, and methods that relate to the real-time monitoring of membrane-mediated processes between two fluids in a receptacle separated by a membrane. The receptacle can be placed in a principal monitoring instrument, which can monitor one or more properties of one of the fluids during the membrane-mediated process. Optionally, one or both fluids can also circulate through external flow paths, allowing reservoirs for volume proportioning between the two fluids. Optionally, the fluids in these external flow paths can be characterized using one or more external monitoring instruments. Optionally, electrodes inside the receptacle can measure conductivity and ionic concentration in the first fluid, and can be used at higher electric fields to affect properties of macromolecules and colloids in the first fluid.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• G01N 1/10 - Devices for withdrawing samples in the liquid or fluent state
• G01N 35/10 - Devices for transferring samples to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
• G01N 21/85 - Investigating moving fluids or granular solids

Abstract

Disclosed herein are compositions comprising recombinant arenavirus monoclonal antibodies and antigen-binding fragments thereof, as well as therapeutic methods using the antibodies. In some embodiments, the antibodies provide pan-arenavirus protection against a number of arenavirus types and strains.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present disclosure provides compounds of the formulae herein (e.g., Formulae I and II), and salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof, which are inhibitors of the YAP-TEAD transcriptional complex. The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, and salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof, and methods of treating or preventing diseases by administering to a subject in need thereof the compounds, and salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof, or pharmaceutical compositions thereof.

IPC Classes  ?

• A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61K 31/33 - Heterocyclic compounds

Abstract

A method for concentrated photovoltaic-thermal power generation includes converting a first portion of concentrated sunlight into electrical power when the first portion of concentrated sunlight illuminates an array of photovoltaic cells; and thermally coupling heat generated by the photovoltaic cells into a heat transfer plate. The method also includes cooling the heat transfer plate by flowing heat transfer fluid through an internal path of a cooling block in direct thermal contact with the heat transfer plate; and flowing the heat transfer fluid through a helical tube to absorb thermal energy from a second portion of concentrated sunlight illuminating the helical tube.

IPC Classes  ?

• H02S 40/44 - Means to utilise heat energy, e.g. hybrid systems producing warm water and electricity at the same time
• F24S 10/70 - Solar heat collectors using working fluids the working fluids being conveyed through tubular absorbing conduits
• F24S 20/20 - Solar heat collectors for receiving concentrated solar energy, e.g. receivers for solar power plants
• F24S 23/72 - Arrangements for concentrating solar rays for solar heat collectors with reflectors with hemispherical reflective surfaces
• F24S 30/452 - Arrangements for moving or orienting solar heat collector modules for rotary movement with two rotation axes with vertical primary axis
• F24S 70/65 - Combinations of two or more absorbing elements
• H01L 31/0304 - Inorganic materials including, apart from doping materials or other impurities, only AIIIBV compounds
• H01L 31/0336 - Inorganic materials including, apart from doping materials or other impurities, semiconductor materials provided for in two or more of groups in different semiconductor regions, e.g. Cu2X/CdX hetero-junctions, X being an element of Group VI of the Periodic System
• H01L 31/05 - Electrical interconnection means between PV cells inside the PV module, e.g. series connection of PV cells
• H01L 31/06 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof adapted as photovoltaic [PV] conversion devices characterised by at least one potential-jump barrier or surface barrier

Abstract

The present invention provides a system and method for capturing images during review of a microscope slide. In certain embodiments, such system and method allow for the capture of images and construction of a composited microscope mosaic image within the workflow of the slide reviewer, such as a pathologist reviewing a tissue sample. In certain embodiments, said mosaic images are whole slide images constructed by and capable of being viewed at variable resolutions and magnifications corresponding to the review of the original microscope slide by the slide reviewer.

IPC Classes  ?

• G06V 10/10 - Image acquisition
• G02B 21/00 - Microscopes
• G02B 21/36 - Microscopes arranged for photographic purposes or projection purposes
• G06V 10/98 - Detection or correction of errors, e.g. by rescanning the pattern or by human interventionEvaluation of the quality of the acquired patterns
• G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
• H04N 5/262 - Studio circuits, e.g. for mixing, switching-over, change of character of image, other special effects

Abstract

Devices and methods for rapidly and incrementally or continuously, measuring rheological properties of polymers under different shear rates. The device includes a pump configured to accept a continuous stream of sample solution during an interval of time, an injector configured to inject a flow of the sample solution through two or more viscometers, and a computing and processing device configured to monitor and measure rheological properties of the solution under at least two shear rates simultaneously in the two or more viscometers.

IPC Classes  ?

• G01N 35/10 - Devices for transferring samples to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
• G01N 11/00 - Investigating flow properties of materials, e.g. viscosity or plasticityAnalysing materials by determining flow properties
• G01N 11/08 - Investigating flow properties of materials, e.g. viscosity or plasticityAnalysing materials by determining flow properties by measuring flow of the material through a restricted passage, e.g. tube, aperture by measuring pressure required to produce a known flow
• G01N 11/14 - Investigating flow properties of materials, e.g. viscosity or plasticityAnalysing materials by determining flow properties by moving a body within the material by using rotary bodies, e.g. vane
• G01N 21/31 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
• G01N 21/47 - Scattering, i.e. diffuse reflection
• G01N 35/08 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor using a stream of discrete samples flowing along a tube system, e.g. flow injection analysis

Abstract

The disclosure relates to human cells and human cell lines comprising a genetic construct, wherein the genetic construct comprises a SARS-CoV-2 RNA, wherein the SARS-CoV-2 RNA does not comprise the spike gene, the envelope gene, the membrane gene or a combination thereof, and methods of making the human cells and human cell lines. The disclosure also includes methods of identifying an agent that inhibits release of extracellular vesicles, wherein the extracellular vesicles comprise SARS-CoV-2 RNA, wherein the SARS-CoV-2 RNA does not comprise the spike gene, the envelope gene, the membrane gene or a combination thereof.

IPC Classes  ?

• A61K 39/21 - Retroviridae, e.g. equine infectious anemia virus
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 15/86 - Viral vectors

Abstract

Disclosed herein are therapeutic agents and combinations of therapeutic agents for use in the treatment of bacterial diseases. Such therapeutic agents and combinations may include azlocillin. Methods of reducing or inhibiting Bartonella bacteria in cells and/or in subjects having Bartonella infections and related disorders by providing therapeutic agents alone or in combination are provided.

IPC Classes  ?

• A61K 31/7052 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
• A61K 31/431 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems containing further heterocyclic ring systems, e.g. ticarcillin, azlocillin, oxacillin
• A61P 31/04 - Antibacterial agents

Abstract

Pseudomonas PseudomonasPseudomonasPseudomonas species.

IPC Classes  ?

• A61K 38/12 - Cyclic peptides
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 31/04 - Antibacterial agents
• C07K 14/32 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Bacillus (G)
• C12N 9/10 - Transferases (2.)

Abstract

A method for preventing and treating micrometastasis in a patient with cancer, especially breast cancer or glioblastoma tumors, by silencing TRAF3IP2 before during or in connection with treatment as described herein.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/04 - Antineoplastic agents specific for metastasis

Abstract

Method and system for detecting disease in blood sample is described. By extracting extracellular vesicles (EVs) from the blood sample and employing liposome fusion probes, it is shown that the test can be completed within hours instead of weeks, and the detection limit can be significantly lowered.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C12Q 1/6851 - Quantitative amplification
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• C12Q 1/6804 - Nucleic acid analysis using immunogens

Abstract

Disclosed herein is a method for diagnosing a mycobacterial infection in a subject. The method comprises performing acetonitrile fractionation of a subject sample to deplete depleted in high molecular weight proteins. The sample is enzymatically digested and analyzed with liquid chromatography tandem mass spectrometry (LC-MS/MS) and bottom-up proteomic analysis to identify a plurality of sample peptides. The sample is then analyzed with a classifier algorithm and a PW species identification score (PWsp) is generated by dividing the number of single and multi-peptide combinations that identify a specific mycobacterium species by the total number of peptide combinations specific for any mycobacteria. A higher PWsp for a given species of mycobacterium indicates a higher likelihood the subject has an infection of that species. This method provides an efficient and accurate way of diagnosing mycobacterial infections in subjects.

IPC Classes  ?

• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
• G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• C12N 1/20 - BacteriaCulture media therefor

Abstract

Escherichia coliEscherichia coli enterotoxin and a saponin, optionally with an additional vaccine component (e.g., an antigen), particularly when used in a vaccine.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/02 - Bacterial antigens
• A61K 39/12 - Viral antigens
• A61P 31/04 - Antibacterial agents
• A61P 31/12 - Antivirals

Abstract

Disclosed herein is a plant-based, blood-free diet formulation for hematophagous insects comprising effective amounts of a plant-based protein source and, in some aspects, a carbohydrate source, wherein the plant-based, blood-free diet formulation is suitable for egg production and colony maintenance of hematophagous insects. In some aspects, such hematophagous insects include, but are not limited to, mosquitoes. In some aspects, the plant-based protein source is derived from hemp seeds. In some aspects, the protein source comprises additional proteins in addition to hemp protein. In some aspects, one or more additional proteins in the formulation is derived from spirulina, soybeans, chia seeds, quinoa, oats, nutritional yeast, and/or green peas.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23K 50/90 - Feeding-stuffs specially adapted for particular animals for insects, e.g. bees or silkworms
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A23K 20/10 - Organic substances

Abstract

Systems and methods to construct Quantum Error Correcting codes from Higher Grassmann Codes. The present disclosure is directed to algebraic codes obtained from families of imbeddings of the Grassmannian, constructed as the composition of a diagonal imbedding followed by a Segre imbedding into various high dimensional projective spaces. As a result, a large family of new error correcting codes is obtained, and the parameters of such codes are determined.

IPC Classes  ?

• G06N 10/00 - Quantum computing, i.e. information processing based on quantum-mechanical phenomena
• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control
• G06N 10/20 - Models of quantum computing, e.g. quantum circuits or universal quantum computers
• G06N 10/70 - Quantum error correction, detection or prevention, e.g. surface codes or magic state distillation
• G06N 10/80 - Quantum programming, e.g. interfaces, languages or software-development kits for creating or handling programs capable of running on quantum computersPlatforms for simulating or accessing quantum computers, e.g. cloud-based quantum computing

Abstract

Embodiments of the instantly claimed inventions include, but are not limited to, chimeric viral constructs, non-human primate models, in vivo screening systems for antiviral agents, gene therapy delivery systems, and methods of making and using the same. In some embodiments, chimeric viral constructs include a non-human primate infecting virus nucleic acid sequence and a exclusively human pathogenic virus nucleic acid sequence for use in creating a non-human primate model and uses thereof. In other embodiments, systems for testing antiviral agents are disclosed. In other embodiments, gene therapy delivery systems disclosed herein can be used to deliver a vector containing or associated with an agent to a human subject for treating conditions of the skin and neuronal ganglia in the subject.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

It has been discovered that immunogens of conserved proteins from Gram-negative bacteria (GNB) co-administered with IL1α provoke a strong T-cell response to the bacteria from which the immunogens were derived. The compositions further provoke cross reactivity with other GNB having homologs of the conserved proteins. This T-cell response is particularly useful in raising effective immune responses to bacterial that infect mucosal surfaces. The disclosure provides compositions and methods for raising robust immune responses to Gram-negative bacteria.

IPC Classes  ?

• A61K 39/02 - Bacterial antigens
• A61K 39/104 - Pseudomonas
• C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria
• C12N 15/117 - Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

The invention relates to the discovery of a previously unknown population of adipocytes marked by active intracellular Wnt/β-catenin signaling. The present invention provides methods of making populations of adipocytes in which the proportion of these “Wnt+ adipocytes” is much higher than those in naturally occurring populations. Wnt+ adipocytes can be used to improve blood glucose control and exosomes secreted by Wnt+ adipocytes can be administered to reduce blood glucose levels in subjects in need thereof.

IPC Classes  ?

• A61K 35/35 - Fat tissueAdipocytesStromal cellsConnective tissues
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 38/28 - Insulins
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

Method and device for detecting SARS-CoV-2 specific T-Cell interferon-gamma activation is described. By using a microfluidic chip to allow ELISpot interferon gamma release assays (IGRA) be performed using a small amount of fingerstick whole blood sample, fast results can be provided with minimal amount of blood sample.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/533 - Production of labelled immunochemicals with fluorescent label
• G01N 33/535 - Production of labelled immunochemicals with enzyme label
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present disclosure describes a method for detecting the presence of Mycobacterium tuberculosis in a bodily fluid sample. The method utilizes CRISPR effector proteins along with a guide RNA and a reporter molecule, such that when the guide RNA hybridizes with a target nucleotide fragment, the CRISPR effector protein cleaves the reporter molecule, resulting in a detectable signal.

IPC Classes  ?

• C12Q 1/6823 - Release of bound markers
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• C12Q 1/6832 - Enhancement of hybridisation reaction

Abstract

The disclosed apparatus, systems and methods relate to ATPA technology that provides a method for the real-time assessment of the polymerization of a sample, e.g., whole blood or blood plasma coagulation, by a non-contact acoustic tweezing device. The acoustic tweezing technology integrates photo-optical tests used in plasma coagulation assays with mechanical (viscoelastic) tests used in whole blood analysis. Its key disruptive features are the increased reliability and accuracy due to non-contact measurement, low sample volume requirement, relatively short procedure time (less than 10 minutes), and the ability to assess the level of Factor XIII function from measurements of the fibrin network formation time.

IPC Classes  ?

• G01N 33/49 - Physical analysis of biological material of liquid biological material blood
• G01N 33/86 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood coagulating time

Abstract

Disclosed are methods of treating a subject having hepatocellular carcinoma (HCC) comprising administering an HCC therapeutic to a subject identified in need thereof, wherein the subject was identified as being in need of thereof by determining the subject had an increased expression level of glypican 3 (GPC3) and/or an increased number of GPC3-enriched exosomes/increase level of exosome-derived GPC3 (eGPC3) as compared to a control. Disclosed are methods of diagnosing and treating a subject comprising detecting whether GPC3 expression is increased in the subject and/or GPC3-enriched exosomes are increased; diagnosing the subject with HCC when the presence of elevated GPC3 and/or an increased number of GPC3-enriched exosomes is detected; and administering a therapeutically effective amount of an HCC therapeutic to the subject. Disclosed are methods of detecting HCC in a subject comprising determining the level of GPC3 positive exosomes and/or the expression level of exosome derived GPC3 in a sample obtained from a subject and comparing the level of GPC3 positive exosomes and/or the expression level of exosome derived GPC3 from the subject to a control, wherein an increase in the level of GPC3 positive exosomes and/or an increase in the expression level of exosome derived GPC3 in the subject, as compared to a control, is a detection of HCC in the subject.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups

Abstract

Disclosed are methods of treating a subject having hepatocellular carcinoma (HCC) comprising administering an HCC therapeutic to a subject identified in need thereof, wherein the subject was identified as being in need of thereof by determining the subject had an increased expression level of glypican 3 (GPC3) and/or an increased number of GPC3-enriched exosomes/increase level of exosome-derived GPC3 (eGPC3) as compared to a control. Disclosed are methods of diagnosing and treating a subject comprising detecting whether GPC3 expression is increased in the subject and/or GPC3-enriched exosomes are increased; diagnosing the subject with HCC when the presence of elevated GPC3 and/or an increased number of GPC3-enriched exosomes is detected; and administering a therapeutically effective amount of an HCC therapeutic to the subject. Disclosed are methods of detecting HCC in a subject comprising determining the level of GPC3 positive exosomes and/or the expression level of exosome derived GPC3 in a sample obtained from a subject and comparing the level of GPC3 positive exosomes and/or the expression level of exosome derived GPC3 from the subject to a control, wherein an increase in the level of GPC3 positive exosomes and/or an increase in the expression level of exosome derived GPC3 in the subject, as compared to a control, is a detection of HCC in the subject.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Goods & Services

Providing courses of instruction at the undergraduate, graduate, postgraduate, professional, and continuing education level

Abstract

Escherichia coliBurkholderia pseudomallei. Burkholderia pseudomallei.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/02 - Bacterial antigens
• A61K 39/108 - EscherichiaKlebsiella
• A61K 39/112 - SalmonellaShigella
• A61K 39/118 - Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
• A61K 39/12 - Viral antigens

Abstract

The present disclosure relates to compounds that act as protein kinase inhibitors, and the synthesis of the same. Further, the present disclosure teaches the utilization of such compounds in a treatment for proliferative diseases, including cancer, particularly breast cancer, and especially ER+ and/or HER2+ breast cancer.

IPC Classes  ?

• C07C 50/12 - Naphthoquinones, i.e. C10H6O2

Abstract

An optoelectronic device includes a thin film of a transition-metal dichalcogenide, a first electrode made of a first metal directly contacting the thin film, and a second electrode made of a second metal directly contacting the thin film. The first metal is molybdenum, titanium, aluminum, tantalum, scandium, or yttrium. The second metal is platinum, nickel, palladium, gold, or cobalt. Depending on the type and doping of the transition-metal dichalcogenide, one of the first and second metals forms an electron selective layer with the transition-metal dichalcogenide and the other of the first and second metals forms a hole selective layer with the transition-metal dichalcogenide. The thin film may be a monolayer or multilayer. The transition-metal dichalcogenide may be molybdenum disulfide. The thin film may be grown via chemical vapor deposition and have an area of 0.25 cm2 or more.

IPC Classes  ?

• H01L 29/786 - Thin-film transistors
• H01L 31/046 - PV modules composed of a plurality of thin film solar cells deposited on the same substrate
• C09K 11/88 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing selenium, tellurium or unspecified chalcogen elements
• H01L 21/283 - Deposition of conductive or insulating materials for electrodes
• H01L 21/441 - Deposition of conductive or insulating materials for electrodes

Abstract

Candida dubliniensisCandida dubliniensis. Kits for use in practicing the methods are also provided.

IPC Classes  ?

• C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
• C12P 19/00 - Preparation of compounds containing saccharide radicals
• C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
• A61K 31/70 - CarbohydratesSugarsDerivatives thereof
• C12N 1/16 - YeastsCulture media therefor

Abstract

Glycosylated, cyclic peptides of Formula (I): A1-cyclo[A2-A3-A4-A5]-A6-O-Carb, Formula (II): A1-cyclo[A5-A3-A4-A2]-A6-O-Carb, and pharmaceutically acceptable salts thereof, are described herein, which are useful, e.g., in treating pain. In some embodiments A1is L-Tyr; A2is a D-Lys, D-Orn, D-Dab, or D-Dpr; A3is L-Trp; A4is L-Phe, A5is an amino acid residue selected from the group consisting of Asp, Glu, iso-Asp, and iso-Glu; A6is (a) a hydroxy-substituted amino acid residue (HO-AA), or (b) an oligopeptide comprising 2 to 5 amino acid residues comprising the HO-AA; Carb is a carbohydrate group bonded to the sidechain oxygen of the HO-AA by a β-D-glycosidic bond, and the C-terminus of A6 optionally is amidated, e.g., as a primary amide.

IPC Classes  ?

• C07K 9/00 - Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequenceDerivatives thereof
• C07K 7/64 - Cyclic peptides containing only normal peptide links
• A61K 38/07 - Tetrapeptides
• A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
• A61P 25/04 - Centrally acting analgesics, e.g. opioids

Abstract

Glycosylated, cyclic peptides of Formula (I): A1-cyclo[A2-A3-A4-A5]-A6-O-Carb, Formula (II): A1-cyclo[A5-A3-A4-A2]-A6-O-Carb, and pharmaceutically acceptable salts thereof, are described herein, which are useful, e.g., in treating pain. In some embodiments A1is L-Tyr; A2is a D-Lys, D-Orn, D-Dab, or D-Dpr; A3is L-Trp; A4is L-Phe, A5is an amino acid residue selected from the group consisting of Asp, Glu, iso-Asp, and iso-Glu; A6is (a) a hydroxy-substituted amino acid residue (HO-AA), or (b) an oligopeptide comprising 2 to 5 amino acid residues comprising the HO-AA; Carb is a carbohydrate group bonded to the sidechain oxygen of the HO-AA by a β-D-glycosidic bond, and the C-terminus of A6 optionally is amidated, e.g., as a primary amide.

IPC Classes  ?

• A61K 38/12 - Cyclic peptides
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61P 25/36 - Opioid-abuse

Abstract

An assay for detection of a target extracellular vesicle in a sample advantageously utilizes copper shells grown on gold nanostructures labeling the target extracellular vesicle to enhance the scattering signal and thereby improve assay sensitivity.

IPC Classes  ?

• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 21/64 - FluorescencePhosphorescence
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

A metalens includes a substrate having a first pixel and a second pixel thereon. The first pixel includes a first periodic array of first antennae each having a first width, a first height, a first electric-dipole resonance, and a first magnetic-dipole resonance. The second pixel includes a second periodic array of second antennae each having a second width and a second height, a second electric-dipole resonance, and a second magnetic-dipole resonance. The first and second periodic arrays have a first period and a second period, respectively. At least one of (i) the first and second widths, (ii) the first and second heights are unequal, and (iii) the first and second periods, are unequal. For each resonance, the center wavelengths of the resonance differs from a design wavelength of the metalens, at which the metalens operates, by less than four times a linewidth of the resonance.

IPC Classes  ?

• G02B 1/00 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements
• H01Q 15/02 - Refracting or diffracting devices, e.g. lens, prism

Abstract

This disclosure describes a method and system for active machine learning model that automatically and continuously improve the model with high accuracy, sensitivity, specificity and universality.

IPC Classes  ?

• G06N 20/00 - Machine learning
• G06N 5/022 - Knowledge engineeringKnowledge acquisition

Abstract

The present disclosure relates to compositions including or obtained from genetically modified bacterial host cells (e.g., E. colt) and methods for using the same for cell-free bacteriophage synthesis (CFBS). In particular, the present technology relates to genetically modified E. coli that overexpress one or more of translation initiation factor IF-3 (infC), OxyS and CyaR and/or repress RecC subunit exonuclease RecBCD, and methods for using the same to obtain improved CFBS yields.

IPC Classes  ?

• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 1/20 - BacteriaCulture media therefor
• C12N 9/22 - Ribonucleases
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli

Abstract

A device for assisting amputees donning prosthetic liners uses a plurality of elongate fingers, radially biased about a central space, to support the liner against the residual limb as the liner is applied. Rollers on each finger provide a frictionless traversal of the device by the limb as the limb is inserted into the central space. Hinged connection of the fingers to a base supporting the fingers, as well as hinges allowing each finger to bend, ensure that engagement between the rollers and the liner is maintained during both limb insertion and withdrawal. Elastic bungees or shock cords joining the fingers provide the radial biasing to the fingers toward the central space.

IPC Classes  ?

• A61F 2/78 - Means for protecting prostheses or for attaching them to the body, e.g. bandages, harnesses, straps, or stockings for the limb stump

Abstract

Described herein are antimicrobial peptides, polynucleotides encoding the peptides, and compositions containing the peptides. Furthermore, described herein are methods for using the peptides, polynucleotides, and compositions for research and therapy.

IPC Classes  ?

• A61K 38/12 - Cyclic peptides
• C07K 7/64 - Cyclic peptides containing only normal peptide links
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
• A01N 63/50 - Isolated enzymesIsolated proteins
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 31/04 - Antibacterial agents
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

Otologic materials and methods are provided. For example, a cell-adhesive, biodegradable hydrogel scaffold loaded with time-released drugs for repairing chronic tympanic membrane perforations is disclosed, methods of making same and administering same are provided. This hydrogel may promote vascular in-growth and epithelial cell growth of the tympanic membrane with the purpose of closing the perforation and providing a barrier between the external and middle ear. The hydrogel is initially a liquid polymer that only gels upon exposure to specific conditions, such as exposure to light. This scaffold may simultaneously induce repair of the tympanic membrane while preventing or alleviating middle ear infection, thus filling a void in current tympanic membrane perforation therapies.

IPC Classes  ?

• A61L 27/14 - Macromolecular materials
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61L 27/20 - Polysaccharides
• A61L 27/52 - Hydrogels or hydrocolloids
• A61L 27/56 - Porous or cellular materials
• A61K 38/38 - Albumins
• A61N 5/06 - Radiation therapy using light

Abstract

Described herein are antiviral peptides, polynucleotides encoding the peptides, and compositions containing the peptides. Furthermore, described herein are methods for using the peptides, polynucleotides, and compositions for treating or inhibiting a viral infection or one or more symptoms of a viral infection.

IPC Classes  ?

• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61P 31/14 - Antivirals for RNA viruses
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61P 31/22 - Antivirals for DNA viruses for herpes viruses

Abstract

Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)). Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating. Further embodiments include methods for making the inventive compound. Additional embodiments of the invention are also discussed herein.

IPC Classes  ?

• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure provides novel antigenic peptides and peptide mixtures, and methods of use for the detection of T. cruzi antibodies in tissue samples and the diagnosis of Chagas disease in a subject.

IPC Classes  ?

• C07K 14/44 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from protozoa
• A61K 38/03 - Peptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants

Abstract

A method and system for detecting TB in a bodily fluid sample are described. By extracting extracellular vesicles (EVs) from the bodily fluid sample and employing antibody-conjugated nanoparticles to capture Mtb-related biomarkers, it is shown that the test can be completed within hours instead of weeks, and the detection limit can be significantly lowered with high accuracy. Additionally, the method and system described is capable of distinguishing between active and latent TB infections.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

The present disclosure describes a method for detecting the presence of pathogens, including SARS-CoV-2, in a sample. The method utilizes CRISPR effector proteins along with a guide RNA and a reporter molecule. RNAs in the sample are first optionally extracted and reverse transcribed, followed by amplification, such that when the guide RNA hybridizes with a target nucleotide fragment in the amplified DNA, the CRISPR effector protein cleaves the reporter molecule, resulting in a detectable signal.

IPC Classes  ?

• C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6816 - Hybridisation assays characterised by the detection means
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

The invention provides compositions and methods for preventing, or reducing the effects of, an infection by coronaviruses, including SARS-CoV-2, that bind human ACE2. The compositions are fusion proteins with mutated forms of the extracellular domain of the ACE2 receptor which can bind viral particles of these coronaviruses. When sprayed or inhaled into an individual’s nasal passages or airway, the inventive fusion proteins bind particles of such coronaviruses, keeping them from reaching and infecting the individual’s cells. When administered parenterally, the fusion proteins can enter the fluid lining the inside of the lung, binding particles of such coronaviruses and keeping them from binding to and infecting cells.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Provided are recombinant adeno-associated virus (rAAV) vectors comprising a transgene to express Pax4; virions comprising said vectors (rAAV virions); methods of their production; methods of their use, including methods for treating diabetes, increasing insulin production and transdifferentiating α-cells to β-cells; pharmaceutical compositions and kits including same.

IPC Classes  ?

• C12N 15/86 - Viral vectors

Abstract

Devices and methods for determining the cumulative distribution of a polymer property in a reactor without physical separation of reaction subcomponents. The device includes a means of measuring an instantaneous property of the polymers being produced in a reaction vessel a plurality of times during a polymerization reaction as well as a means of determining the corresponding change in polymer concentration in the reaction vessel between measurements of the instantaneous polymer property. The device also includes a means of computing a statistical distribution appropriate to the polymer characteristic and applying the statistical distribution to a recently measured instantaneous value of the polymer property so as to have an instantaneous distribution of the polymer property and a means of adding together the instantaneous distributions of the polymer property in order to obtain the cumulative distribution of the polymer property in the reactor.

IPC Classes  ?

• G01N 21/75 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
• B01J 19/00 - Chemical, physical or physico-chemical processes in generalTheir relevant apparatus
• C08F 20/56 - AcrylamideMethacrylamide

Abstract

Treating a human coronavirus (hCoV) infection includes administering an effective amount of an inhibitor of an α5- or αv-containing integrin to a subject in need thereof. The integrin inhibitor can be ATN-161. The hCoV can be SARS-CoV or SARS-CoV-2.

IPC Classes  ?

• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Burkholderia pseudomallei complex can be used as adjuvants in compositions and methods to potentiate the immune response to immunogens.

IPC Classes  ?

• A61K 39/02 - Bacterial antigens
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/12 - Viral antigens

Abstract

The present disclosure relates to cancer tumor stroma models with dense stroma and heterogeneous patterns of ECM anisotropy. The invention herein will enable more accurate modeling of tumor pathophysiology, drug delivery, and novel treatment methods impacted by ECM density.

IPC Classes  ?

• C12N 5/09 - Tumour cells
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Disclosed are designs that enable rapid production of fully vascularized milliscale explant tissues that will enable preservation and expansion of this precious clinical resource and simultaneous investigation of potential biological underpinnings of diseases. Models include triple negative breast cancer or aggressive lung cancer and quiescent lung interstitium integrated in a robust, easily adaptable millifluidic device. Devices will allow any laboratory that use cultures and/or organoids to construct complex multi-tissue/ organ systems. Implementation of these devices can model multiple organ pathologies induced by tumor-derived factors.

IPC Classes  ?

• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The invention provides compositions, methods, kits, and devices for detecting the number and locations of polymorphic LINE-1 (pL1s) elements present in the genome of an individual and for detecting previously unknown pL1s. The inventive compositions, methods, kits, and devices permit the identification of numbers and patterns of pL1 insertions that render a person with such numbers and patterns at higher risk of developing cancer or cognitive disorders compared to persons without such numbers and patterns.

IPC Classes  ?

• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• C12Q 1/6834 - Enzymatic or biochemical coupling of nucleic acids to a solid phase
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Disclosed are anthranilic amide derivatives having the formula: Disclosed are anthranilic amide derivatives having the formula: Disclosed are anthranilic amide derivatives having the formula: Compositions are disclosed that include the anthranilic amide derivatives and the use of the anthranilic amide derivatives for the manufacture of a medicament. Further disclosed are methods of inhibiting or treating cancer, inhibiting or reversing an epithelial to mesenchymal cellular transition, and/or inhibiting MEK1/2 and/or MEK 5 enzymatic activity in a subject by administering to the subject an effective amount of a disclosed anthranilic amide derivative.

IPC Classes  ?

• C07D 295/16 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
• C07C 229/58 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho- position having the nitrogen atom of at least one of the amino groups further bound to a carbon atom of a six-membered aromatic ring, e.g. N-phenyl-anthranilic acids
• C07C 237/30 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
• C07C 237/32 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
• C07C 237/34 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
• C07C 237/36 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups

Abstract

The present disclosure describes a method for detecting the presence of Mycobacterium tuberculosis in a bodily fluid sample. The method utilizes CRISPR effector proteins along with a guide RNA and a reporter molecule, such that when the guide RNA hybridizes with a target nucleotide fragment, the CRISPR effector protein cleaves the reporter molecule, resulting in a detectable signal.

IPC Classes  ?

• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

The disclosure relates to a system and method of using the system to detect and monitor afferent synaptic nerve fiber function in vitro. The disclosure also relates to a method of screening for test agents or compounds that modulate nerve function, such as test agents that modulate pain sensation in a human subject, by exposing one or a plurality of test agents to systems comprising a first and second spheroid, wherein the first spheroid comprise cells from a mammalian dorsal root ganglia and the second spheroid comprises cells from a mammalian spinal cord.

IPC Classes  ?

• C12N 5/0793 - Neurons
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The disclosed apparatus, systems and methods relate to technology that provides a method for the assessment of the polymerization of a sample, e.g., whole blood or blood plasma coagulation, by a non-contact acoustic tweezing device via the application of a sweeping frequency to the levitating sample and the corresponding assessment of extracted sample parameters.

IPC Classes  ?

• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• G01N 29/036 - Analysing fluids by measuring frequency or resonance of acoustic waves
• G01N 29/34 - Generating the ultrasonic, sonic or infrasonic waves
• G01N 15/02 - Investigating particle size or size distribution

Goods & Services

Organizing book festivals for cultural or entertainment purposes

Abstract

A three-dimensional (3D) microelectrode array for in vitro electrical and microfluidic interrogation of electrogenic cell constructs includes a substrate having a plurality of micro vias. A hypodermic microneedle is received within each micro via of a first subgroup of the plurality of micro vias and each has a length that exceeds the thickness of the substrate to form a hypodermic microneedle array on the top face of the substrate. Metallic traces are formed on the bottom face and interconnect the hypodermic microneedles. A culturing area is formed in the top face.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

The present disclosure describes chemical blends and methods of using those blends for multipurpose environmental disinfection of objects and surfaces. The disclosed chemical blends composition comprising stabilized chlorine dioxide; a quaternary ammonium salt; ammonium phosphate; nonionized ammonia; buffer, surfactant, stabilizer; and water. The composition is configured to inactivate the full range of environmental and pathogenic organisms, including amoeba, bacterial spores, vegetative bacteria, fungi, viruses, parasites (eggs and oocysts) and toxic microbial products.

IPC Classes  ?

• A01N 33/02 - AminesQuaternary ammonium compounds
• A61K 33/20 - Elemental chlorineInorganic compounds releasing chlorine
• A01N 59/00 - Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
• A01N 31/08 - Oxygen or sulfur directly attached to an aromatic ring system
• A01N 25/08 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests containing solids as carriers or diluents
• A01N 25/00 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests

Abstract

BartonellaBartonellaBartonella infections and related disorders by providing therapeutic agents alone or in combination are provided.

IPC Classes  ?

• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/431 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems containing further heterocyclic ring systems, e.g. ticarcillin, azlocillin, oxacillin
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins

Abstract

Provided are synthetic dendrimer calibrants for mass spectrometry. The calibrants are distinguished by their relative case and rapidity of synthesis, comparatively low cost, long shelf life, high purity, and amenability to batch synthesis as mixtures. The latter characteristic enables parallel preparation of higher molecular weight compounds displaying useful distributions of discrete molecular weights, thereby providing multi-point mass spectrometry calibration standards. Methods of making, tuning and using said calibrants are provided.

IPC Classes  ?

• H01J 49/00 - Particle spectrometers or separator tubes
• C07D 319/06 - 1,3-DioxanesHydrogenated 1,3-dioxanes not condensed with other rings
• C07D 493/22 - Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings